Butyrate has been reported to exert immunomodulatory effects and activate antitumor immunity by increasing MHC-I levels in tumor cells and inducing CXCL10 secretion, leading to CD8 + T cell recruitment, which were also confirmed in the present study. The gene discussed is CD8A; the disease is neoplasm.